NRX Pharmaceuticals (FRA:B1Q) Scaled Net Operating Assets: -1.53 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:B1Q NRX Pharmaceuticals Inc FRA:B1Q
33 GF Score
Price €3.79
! 4 Warning Signs
View Full Analysis

What is NRX Pharmaceuticals Scaled Net Operating Assets?

NRX Pharmaceuticals FRA:B1Q +5.42% 33 Scaled Net Operating Assets is -1.53 as of Mar. 2026. GuruFocus rates FRA:B1Q with a GF Score™ of 33/100. The stock has 4 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NRX Pharmaceuticals's operating assets for the quarter that ended in Mar. 2026 was €4.49 Mil. NRX Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2026 was €21.44 Mil. NRX Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was €11.06 Mil. Therefore, NRX Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -1.53.


NRX Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for NRX Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NRX Pharmaceuticals Scaled Net Operating Assets Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial -2.30 -0.07 -0.27 -2.58 -5.66

NRX Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.92 -3.49 -4.58 -1.54 -1.53

FRA:B1Q vs CRBP, PRQR, TNYA: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, NRX Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NRX Pharmaceuticals Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's Scaled Net Operating Assets falls into.


FRA:B1Q
33GF Score
NRX Pharmaceuticals Inc FRA:B1Q
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NRX Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NRX Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(4.405-24.136)/3.487
=-5.66

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=11.064 - 6.659
=4.405

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=24.675 - 0.269 - 0.27
=24.136

NRX Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(4.489-21.439)/11.064
=-1.53

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10.296 - 5.807
=4.489

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=22.247 - 0.47 - 0.338
=21.439

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -1.53 mean?
NRX Pharmaceuticals (FRA:B1Q) has a Scaled Net Operating Assets of -1.53 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on NRX Pharmaceuticals and its competitors.
Is NRX Pharmaceuticals' Scaled Net Operating Assets too high?
NRX Pharmaceuticals' current Scaled Net Operating Assets is -1.53. Overall, NRX Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NRX Pharmaceuticals' Scaled Net Operating Assets compare to CRBP and PRQR?
NRX Pharmaceuticals' Scaled Net Operating Assets of -1.53 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on NRX Pharmaceuticals and its competitors. NRX Pharmaceuticals's current Scaled Net Operating Assets is -1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NRX Pharmaceuticals stock overvalued right now?
NRX Pharmaceuticals (FRA:B1Q) has a current Scaled Net Operating Assets of -1.53. The current Scaled Net Operating Assets is -1.53. NRX Pharmaceuticals' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For NRX Pharmaceuticals (FRA:B1Q), the current Scaled Net Operating Assets is -1.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NRX Pharmaceuticals Business Description

Other Exchanges NRXP:USA
Address 1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
33GF Score

Get the complete analysis for FRA:B1Q

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.79
Price